Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial

被引：0
|
作者：
Viteri, S. [1 ]
Felip, E. [2 ]
Griesinger, F. [3 ]
Garassino, M. C. [4 ]
Sakai, H. [5 ]
Le, X. [6 ]
Veillon, R. [7 ]
Smit, E. F. [8 ]
Raskin, J. [9 ]
Thomas, M. [10 ,11 ,12 ]
Ahn, M-J. [13 ]
Vlassak, S. [14 ,15 ]
Bruns, R. [16 ]
Johne, A. [17 ]
Paik, P. K. [18 ]
机构：
[1] Dexeus Univ Hosp, Inst Oncol Dr Rosell, QuironSalud Grp, Barcelona, Spain
[2] Vall dHebron Inst Oncol VHIO, Dept Oncol, Barcelona, Spain
[3] Carl von Ossietzky Univ Oldenburg, Dept Hematol & Oncol, Pius Hosp, Oldenburg, Germany
[4] Univ Chicago, Sect Hematol Oncol, Dept Med, Knapp Ctr Biomed Discovery, Chicago, IL USA
[5] Ageo Cent Gen Hosp, Dept Thorac Oncol, Ageo, Japan
[6] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[7] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[8] Univ Med Ctr, Dept Pulm Dis, Leiden, Netherlands
[9] Antwerp Univ Hosp UZA, Dept Pulmonol & Thorac Oncol, Edegem, Belgium
[10] Univ Heidelberg Hosp, Thoraxklin & Natl Ctr Tumor Dis, Heidelberg, Germany
[11] Translat Lung Res Ctr Heidelberg TLRC H, Heidelberg, Germany
[12] German Ctr Lung Res DZL, Heidelberg, Germany
[13] Sungkyunkwan Univ, Dept Med, Sect Hematol Oncol, Samsung Med Ctr,Sch Med, Seoul, South Korea
[14] Global Med Affairs, Merck NVSA, Antwerp, Belgium
[15] Merck KGaA, Darmstadt, Germany
[16] Merck Healthcare KGaA, Depat Biostat, Darmstadt, Germany
[17] Merck Healthcare KGaA, Global Clin Dev, Darmstadt, Germany
[18] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1380P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC
    Griesingerl, Frank
    Garassino, Marina
    Felip, Enriqueta
    Sakai, Hiroshi
    Le, Xiuning
    Veillon, Remi
    Smit, Egbert
    Raskin, Jo
    Thomas, Michael
    Ahn, Myung-Ju
    Lee, Matthew
    Vlassak, Soetkin
    Bruns, Rolf
    Johne, Andreas
    Palle, Paul K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E37 - E38
  • [2] Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
    Scherz, A.
    Felip, E.
    Garassino, M.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E.
    Mazieres, J.
    Cortot, A.
    Raskin, J.
    Viteri, S.
    Iams, W. Thomas
    Kim, H. R.
    Yang, J. -J.
    Stroh, C.
    Otto, G.
    Bruns, R.
    Paik, P.
    SWISS MEDICAL WEEKLY, 2021, 151 : 36 - 36
  • [3] Intracranial Activity of Tepotinib in Patients (pts) With MET exon 14 (METex14) Skipping NSCLC Enrolled in VISION
    Bestvina, C. M.
    Patel, J. D.
    Le, X.
    Veillon, R.
    Anderson, I.
    Demedts, I.
    Garassino, M.
    Mazieres, J.
    Morise, M.
    Smit, E.
    Eggleton, S. P.
    O'Brate, A.
    Otto, G.
    Bruns, R.
    Schumacher, K. M.
    Paik, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (02): : E14 - E15
  • [4] Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
    Yang, J. C-H.
    Le, X.
    Cho, B. C.
    Han, J-Y.
    Morise, M.
    Chen, Y-M.
    Kang, J-H.
    Kato, T.
    Takeoka, H.
    Chikamori, K.
    Sakai, H.
    Park, K.
    Wu, Y-L.
    Schumacher, K.
    Bruns, R.
    Straub, J.
    Paik, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1390 - S1391
  • [5] Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.
    Patel, Jyoti D.
    Le, Xiuning
    Veillon, Remi
    Anderson, Ian Churchill
    Bestvina, Christine M.
    Demedts, Ingel
    Garassino, Marina Chiara
    Mazieres, Julien
    Morise, Masahiro
    Smit, Egbert F.
    Eggleton, S. Peter
    OBrate, Aurora
    Otto, Gordon
    Bruns, Rolf
    Schumacher, Karl-Maria
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping
    Yang, J. C-H.
    Ahn, M-J.
    Sakai, H.
    Morise, M.
    Kato, T.
    Chen, Y-M.
    Han, J-Y.
    Yang, J-J.
    Zhao, J.
    Huang, J.
    Berghoff, K.
    Bruns, R.
    Otto, G.
    Le, X.
    Paik, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S41 - S42
  • [7] Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC
    Garassino, Marina C.
    Le, Xiuning
    Iam, Wade T.
    Felip, Enriqueta
    Sakai, Hiroshi
    Veillon, Remi
    Smit, Egbert F.
    Mazieres, Julien
    Raskin, Jo
    Cortot, Alexis B.
    Berghoff, Karin
    Bruns, Rolf
    Otto, Gordon
    Paik, Paul K.
    CANCER RESEARCH, 2022, 82 (12)
  • [8] Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial
    Morise, Masahiro
    Sakai, Hiroshi
    Veillon, Remi
    Le, Xiuning
    Felip, Enriqueta
    Garassino, Marina Chiara
    Cortot, Alexis B.
    Smit, Egbert
    Park, Keunchil
    Griesinger, Frank
    Britschgi, Christian
    Wu, Yi-Long
    Berghoff, Karin
    Otto, Gordon
    Bruns, Rolf
    Paik, Paul
    ANNALS OF ONCOLOGY, 2021, 32 : S291 - S291
  • [9] Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial
    Veillon, R.
    Sakai, H.
    Le, X.
    Felip, E.
    Garassino, M. C.
    Cortot, A.
    Smit, E.
    Park, K.
    Griesinger, F.
    Britschgi, C.
    Wu, Y.
    Berghoff, K.
    Otto, G.
    Bruns, R.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S231 - S231
  • [10] Treatment sequencing in the VISION study of tepotinib in patients with METexon 14 (METex14) skipping NSCLC
    Griesinger, F.
    Garassino, M. C.
    Felip, E.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E. F.
    Raskin, J.
    Thomas, M.
    Ahn, M-J.
    Vlassak, S.
    Bruns, R.
    Johne, A.
    Paik, P. K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S60 - S61
12345